Phosphorylcholine polymer nanocapsules prolong the circulation time and reduce the immunogenicity of therapeutic proteins

• DOI: 10.1007/s12274-016-0991-3
• Publication Date: 2016-02-01T11:23:38Z
• Authors: Sheng Liang; Yang Liu; Xin Jin; Gan Liu; Jing Wen; Linlin Zhang; Jie Li; Xubo Yuan; Irvin S. Y. Chen; Wei Chen; Hui Wang; Linqi Shi; Xinyuan Zhu; Yunfeng Lu
• Keywords: Phosphorylcholine; Nanocapsules; Protein Adsorption

Protein therapy, wherein therapeutic proteins are delivered to treat disorders, is considered the safest and most direct approach for treating diseases. However, its applications are highly limited by the paucity of efficient strategies for delivering proteins and the rapid clearance of therapeutic proteins in vivo after their administration. Here, we demonstrate a novel strategy that can significantly prolong the circulation time of therapeutic proteins as well as minimize their immunogenicity. This is achieved by encapsulating individual protein molecules with a thin layer of crosslinked phosphorylcholine polymer that resists protein adsorption. Through extensive cellular studies, we demonstrate that the crosslinked phosphorylcholine polymer shell effectively prevents the encapsulated protein from being phagocytosed by macrophages, which play an essential role in the clearance of nanoparticles in vivo. Moreover, the polymer shell prevents the encapsulated protein from being identified by immune cells. As a result, immune responses against the therapeutic protein are effectively suppressed. This work describes a feasible method to prolong the circulation time and reduce the immunogenicity of therapeutic proteins, which may promote the development and application of novel protein therapies in the treatment of diverse diseases.